# ZUSDURI (mitomycin) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mitomycin

> The PDUFA target action date for ZUSDURI (mitomycin), sponsored by UroGen Pharma Ltd. (URGN), is June 14, 2027, for with recurrent low-grade intermediate risk NMIBC. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### When is the ZUSDURI (mitomycin) PDUFA date?

The PDUFA target action date for ZUSDURI (mitomycin), sponsored by UroGen Pharma Ltd. (URGN), is June 14, 2027, for with recurrent low-grade intermediate risk NMIBC. Status: scheduled. Press release filed with the SEC (EX-99): "The FDA accepted UroGen's NDA for UGN-103 (next-generation novel mitomycin-based formulation) for review; PDUFA goal date set for June 14, 2027" Last confirmed November 4, 2026. [Calendar and source filings](https://sec-api.dev/pdufa/mitomycin)

Source: Press release filed with the SEC (EX-99), accession 0001437749-26-034769, https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/pdufa/mitomycin#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | ZUSDURI (mitomycin) |
| Codes | UGN-104, UGN-103, UGN-102 |
| Sponsor | UroGen Pharma Ltd. (URGN) https://sec-api.dev/companies/urgn/catalysts |
| Indications | [with recurrent low-grade intermediate risk nmibc](https://sec-api.dev/indications/with-recurrent-low-grade-intermediate-risk-nmibc), [recurrent low-grade intermediate risk nmibc](https://sec-api.dev/indications/recurrent-low-grade-intermediate-risk-nmibc), with recurrent low-grade intermediate risk nmibc supported, recurrent, papillary-only high-risk nmibc, recurrent lg-ir-nmibc, with recurrent low-grade intermediate risk non-muscle invasive bladder cancer |
| Modality |  |
| FDA designations | priority review |

## Timeline

### April 15, 2020: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA211728 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20200415, review_priority PRIORITY; sponsor_name UROGEN PHARMA; product JELMYTO (MITOMYCIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211728%22

### Jan 2024: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-03-10, last confirmed 2025-05-12.
- SEC Form 10-Q (accession 0001437749-25-015956): "The FDA also agreed that the UGN-102 NDA can utilize a rolling review, allowing for early submission of the CMC sections of the NDA, which we submitted in January 2024." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-006842): "The FDA also agreed that the UGN-102 NDA can utilize a rolling review, allowing for early submission of the Chemistry, Manufacturing and Controls ("CMC") sections of the NDA, which we submitted in January 2024." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm
- SEC Form 10-K (accession 0001437749-25-006842): "The FDA also agreed that the UGN-102 NDA can utilize a rolling review, allowing for early submission of the CMC sections of the NDA, which we submitted in January 2024." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm

### Apr 2024: trial start

- Status: completed. Date confidence: month. Stage: 3. Indication: recurrent low-grade intermediate risk NMIBC.
- First seen 2025-03-10, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001437749-26-034780): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm
- SEC Form 10-Q (accession 0001437749-26-025794): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926025794/urgn20260630_10q.htm
- SEC Form 10-Q (accession 0001437749-26-015019): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926015019/urgn20260331_10q.htm
- SEC Form 10-K (accession 0001437749-26-006234): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm
- SEC Form 10-K (accession 0001437749-26-006234): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study is evaluating the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm
- SEC Form 10-Q (accession 0001437749-25-033468): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study that will evaluate the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774925033468/urgn20250930_10q.htm
- SEC Form 10-Q (accession 0001437749-25-025243): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study that will evaluate the efficacy and safety of UGN-103 in recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774925025243/urgn20250630_10q.htm
- SEC Form 10-Q (accession 0001437749-25-015956): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study that will evaluate the efficacy and safety of UGN-103 in recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-006842): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study that will evaluate the efficacy and safety of UGN-103 in low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm

### Apr 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month. Stage: 3. Indication: recurrent low-grade intermediate risk NMIBC.
- First seen 2025-03-10, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001437749-26-034780): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm
- SEC Form 10-Q (accession 0001437749-26-025794): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926025794/urgn20260630_10q.htm
- SEC Form 10-Q (accession 0001437749-26-015019): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926015019/urgn20260331_10q.htm
- SEC Form 10-K (accession 0001437749-26-006234): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study evaluating the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm
- SEC Form 10-K (accession 0001437749-26-006234): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study is evaluating the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm
- SEC Form 10-Q (accession 0001437749-25-033468): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study that will evaluate the efficacy and safety of UGN-103 in patients with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774925033468/urgn20250930_10q.htm
- SEC Form 10-Q (accession 0001437749-25-025243): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study that will evaluate the efficacy and safety of UGN-103 in recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774925025243/urgn20250630_10q.htm
- SEC Form 10-Q (accession 0001437749-25-015956): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study that will evaluate the efficacy and safety of UGN-103 in recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-006842): "In April 2024, we announced that the FDA accepted our Investigational New Drug Application ("IND") for UGN-103 and we initiated our Phase 3 UTOPIA trial, a single-arm, multicenter study that will evaluate the efficacy and safety of UGN-103 in low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm

### Jun 2024: PDUFA date

- Status: delayed. Date confidence: month.
- First seen 2025-01-14, last confirmed 2025-01-14.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-005649): "Acceptance Anticipated Results NDA Submission 1 2 Of NDA ODAC PDUFA June 2024 August 2024 October 2024 Q2 2025 June 13, 2025 1." https://www.sec.gov/Archives/edgar/data/1668243/000119312525005649/d903812dex991.htm

### Aug 2024: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-03-10, last confirmed 2025-05-12.
- SEC Form 10-Q (accession 0001437749-25-015956): "In August 2024, the Company completed the submission of the rolling new drug application ("NDA") for UGN-102." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm
- SEC Form 10-Q (accession 0001437749-25-015956): "In August 2024, we completed the submission of the rolling NDA for UGN-102." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-006842): "In August 2024, we completed the submission of the rolling NDA for UGN-102." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm
- SEC Form 10-K (accession 0001437749-25-006842): "In August 2024, we completed the submission of a rolling NDA for UGN-102." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm
- SEC Form 10-K (accession 0001437749-25-006842): "In August 2024, the Company completed the submission of the rolling NDA for UGN-102." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-015955): "UroGen completed the submission of a rolling NDA in August 2024, ahead of schedule." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm

### Oct 2024: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-03-10, last confirmed 2026-11-04.
- SEC Form 10-K (accession 0001437749-25-006842): "In October 2024, we initiated a Phase 3 study to explore the safety and efficacy of UGN-103 in low-grade, intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm
- SEC Form 10-Q (accession 0001437749-26-034780): "In October 2024, we announced the first patient dosed in the UTOPIA trial, and in July 2025, we announced the completion of patient enrollment with 99 patients enrolled across multiple centers globally." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm
- SEC Form 10-Q (accession 0001437749-26-025794): "In October 2024, we announced the first patient dosed in the UTOPIA trial, and in July 2025, we announced the completion of patient enrollment with 99 patients enrolled across multiple centers globally." https://www.sec.gov/Archives/edgar/data/1668243/000143774926025794/urgn20260630_10q.htm
- SEC Form 10-Q (accession 0001437749-26-015019): "In October 2024, we announced the first patient dosed in the UTOPIA trial, and in July 2025, we announced the completion of patient enrollment with 99 patients enrolled across multiple centers globally." https://www.sec.gov/Archives/edgar/data/1668243/000143774926015019/urgn20260331_10q.htm
- SEC Form 10-K (accession 0001437749-26-006234): "In October 2024, we announced the first patient dosed in the UTOPIA trial, and in July 2025, we announced the completion of patient enrollment with 99 patients enrolled across multiple centers globally." https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm
- SEC Form 10-Q (accession 0001437749-25-033468): "In October 2024, we announced the first patient dosed in the UTOPIA trial, and in July 2025, we announced the completion of patient enrollment with 99 patients enrolled across multiple centers globally." https://www.sec.gov/Archives/edgar/data/1668243/000143774925033468/urgn20250930_10q.htm
- SEC Form 10-Q (accession 0001437749-25-025243): "In October 2024, we announced the first patient dosed in the UTOPIA trial, and in July 2025, we announced the completion of patient enrollment with 99 patients enrolled across multiple centers globally." https://www.sec.gov/Archives/edgar/data/1668243/000143774925025243/urgn20250630_10q.htm

### Oct 2024: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2025-03-10, last confirmed 2025-05-12.
- SEC Form 10-Q (accession 0001437749-25-015956): "While the FDA accepted our NDA for UGN-102 in October 2024 and assigned a PDUFA goal date of June 13, 2025, there is no guarantee that the PDUFA goal date will not be delayed or that the FDA will eventually approve UGN-102 for the indication and patient population that we request or approve the labeling that we believe is necessary or desirable for the successful commercialization of UGN-102, as the FDA does not always meet its PDUFA dates and it has the authority to refuse to approve NDAs for a variety of reasons." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-006842): "In October 2024, the FDA accepted our NDA for UGN-102 and assigned a PDUFA goal date of June 13, 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm
- SEC Form 10-K (accession 0001437749-25-006842): "While the FDA accepted our NDA for UGN-102 in October 2024, there is no guarantee that the FDA will eventually approve UGN-102 for the indication and patient population that we request or approve the labeling that we believe is necessary or desirable for the successful commercialization of UGN-102, as the FDA has the authority to refuse to approve NDAs for a variety of reasons." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm
- SEC Form 10-Q (accession 0001437749-25-015956): "In October 2024, the FDA accepted the Company's NDA for UGN-102 (mitomycin) for intravesical solution and assigned a Prescription Drug User Fee Act ("PDUFA") goal date of June 13, 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm
- SEC Form 10-Q (accession 0001437749-25-015956): "In October 2024, the FDA accepted our NDA for UGN-102 (mitomycin) for intravesical solution and assigned a Prescription Drug User Fee Act ("PDUFA") goal date of June 13, 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-006842): "In October 2024, the FDA accepted our NDA for UGN-102 (mitomycin) for intravesical solution and assigned a Prescription Drug User Fee Act ("PDUFA") goal date of June 13, 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm
- SEC Form 10-K (accession 0001437749-25-006842): "In October 2024, the FDA accepted the Company's NDA for UGN-102 (mitomycin) for intravesical solution and assigned a Prescription Drug User Fee Act ("PDUFA") goal date of June 13, 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm

### Feb 2025: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2025-08-07, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001437749-26-034780): "In February 2025, the FDA accepted our IND for UGN-104, and we initiated a Phase 3 trial of UGN-104 in low-grade UTUC in June 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm
- SEC Form 10-Q (accession 0001437749-26-025794): "In February 2025, the FDA accepted our IND for UGN-104, and we initiated a Phase 3 trial of UGN-104 in low-grade UTUC in June 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774926025794/urgn20260630_10q.htm
- SEC Form 10-Q (accession 0001437749-26-015019): "In February 2025, the FDA accepted our IND for UGN-104, and we initiated a Phase 3 trial of UGN-104 in low-grade UTUC in June 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774926015019/urgn20260331_10q.htm
- SEC Form 10-K (accession 0001437749-26-006234): "In February 2025, the FDA accepted our IND for UGN-104, and we initiated a Phase 3 trial of UGN-104 in low-grade UTUC in June 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm
- SEC Form 10-Q (accession 0001437749-25-033468): "In February 2025, the FDA accepted our IND for UGN-104, and we initiated a Phase 3 trial of UGN-104 in low-grade UTUC in June 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925033468/urgn20250930_10q.htm
- SEC Form 10-Q (accession 0001437749-25-025243): "In February 2025, the FDA accepted our IND for UGN-104, and we initiated a Phase 3 trial of UGN-104 in low-grade UTUC in June 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925025243/urgn20250630_10q.htm

### March 10, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-03-10, last confirmed 2025-03-10.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-006757): "UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102" https://www.sec.gov/Archives/edgar/data/1668243/000143774925006757/ex_785682.htm

### mid-2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3.
- First seen 2025-03-10, last confirmed 2025-05-12.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-015955): "UroGen plans to initiate a Phase 3 trial to explore the safety and efficacy of UGN-104 by mid-2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-006757): "UroGen plans to initiate a Phase 3 trial to explore the safety and efficacy of UGN-104, its next generation product for LG-UTUC in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006757/ex_785682.htm
- SEC Form 10-Q (accession 0001437749-25-015956): "We plan to initiate a Phase 3 trial of UGN-104 in low-grade UTUC in mid-2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-006842): "We plan to initiate a Phase 3 trial of UGN-104 in low-grade UTUC in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm
- SEC Form 10-K (accession 0001437749-25-006842): "We also plan to initiate a Phase 3 study in the first half of 2025 to explore the safety and efficacy of UGN-104 in low-grade UTUC." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm

### May 21, 2025: FDA advisory committee meeting

- Status: completed. Date confidence: exact.
- First seen 2025-05-12, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "On the morning of May 21, 2025, the Committee will discuss new drug application (NDA) 215793, for (mitomycin) intravesical solution, submitted by UroGen Pharma, Inc. The proposed indication (use) is for the treatment of adult patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)." https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025
- Press release filed with the SEC (EX-99) (accession 0001437749-25-015955): "The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) meeting on May 21, 2025 to discuss the UGN-102 NDA." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm
- SEC Form 10-Q (accession 0001437749-25-015956): "The FDA has scheduled an Oncologic Drugs Advisory Committee meeting for May 21, 2025 to review the NDA for UGN-102." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-015955): "Oncologic Drugs Advisory Committee scheduled for May 21, 2025" https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm

### June 12, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: with recurrent low-grade intermediate risk NMIBC.
- First seen 2025-06-13, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215793 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250612, review_priority STANDARD; sponsor_name UROGEN PHARMA; product ZUSDURI (MITOMYCIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215793%22
- Press release filed with the SEC (EX-99) (accession 0001437749-26-006233): "ZUSDURI was approved by the U.S. Food and Drug Administration (FDA) on June 12, 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774926006233/ex_925621.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-025242): "On June 12, 2025, the U.S. Food and Drug Administration (FDA) approved ZUSDURI (formerly UGN-102), the first and only FDA-approved medication for adults with recurrent LG-IR-NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774925025242/ex_847591.htm
- SEC Form 10-Q (accession 0001437749-26-034780): "On June 12, 2025, the U.S. Food and Drug Administration ("FDA") approved our new drug application ("NDA") for Zusduri (formerly known as UGN-102) for the treatment of adults with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm
- SEC Form 10-Q (accession 0001437749-26-025794): "On June 12, 2025, the U.S. Food and Drug Administration ("FDA") approved our new drug application ("NDA") for Zusduri (formerly known as UGN-102) for the treatment of adults with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926025794/urgn20260630_10q.htm
- SEC Form 10-Q (accession 0001437749-26-015019): "On June 12, 2025, the U.S. Food and Drug Administration ("FDA") approved our new drug application ("NDA") for Zusduri (formerly known as UGN-102) for the treatment of adults with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926015019/urgn20260331_10q.htm
- SEC Form 10-K (accession 0001437749-26-006234): "On June 12, 2025, the U.S. Food and Drug Administration ("FDA") approved our new drug application ("NDA") for Zusduri (formerly known as UGN-102) for the treatment of adults with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/urgn20251231_10k.htm
- SEC Form 10-Q (accession 0001437749-25-033468): "On June 12, 2025, the U.S. Food and Drug Administration ("FDA") approved our new drug application ("NDA") for Zusduri (formerly known as UGN-102) for the treatment of adults with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774925033468/urgn20250930_10q.htm
- SEC Form 10-Q (accession 0001437749-25-025243): "On June 12, 2025, the U.S. Food and Drug Administration ("FDA") approved our new drug application ("NDA") for Zusduri (formerly known as UGN-102) for the treatment of adults with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774925025243/urgn20250630_10q.htm
- SEC Form 8-K (accession 0001193125-25-140339): "On June 12, 2025, the U.S. Food and Drug Administration ("FDA") approved ZUSDURI™ (mitomycin), formerly known as UGN-102, a sustained-release gel formulation of mitomycin for the treatment of adults with recurrent low-grade intermediate risk non-muscle invasive bladder cancer ("LG-IR-NMIBC")." https://www.sec.gov/Archives/edgar/data/1668243/000119312525140339/d98388d8k.htm
- SEC Form 10-Q (accession 0001437749-26-034780): "On June 12, 2025, the FDA approved our NDA for Zusduri (mitomycin) for intravesical solution, formerly known as UGN-102, for the treatment of adults with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm
- SEC Form 10-Q (accession 0001437749-26-025794): "On June 12, 2025, the FDA approved our NDA for Zusduri (mitomycin) for intravesical solution, formerly known as UGN-102, for the treatment of adults with recurrent low-grade intermediate risk NMIBC." https://www.sec.gov/Archives/edgar/data/1668243/000143774926025794/urgn20260630_10q.htm

### June 13, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-01-14, last confirmed 2025-05-12.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-015955): "New Drug Application for UGN-102 on track for FDA-PDUFA target action date of June 13, 2025; assuming approval, commercial launch to immediately follow with product availability in July" https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-015955): "The FDA accepted the NDA for UGN-102 and assigned a PDUFA goal date of June 13, 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015955/ex_815371.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-006757): "New drug application (NDA) for UGN-102 under review by the FDA; Prescription Drug User Fee Act (PDUFA) target action date set for June 13, 2025" https://www.sec.gov/Archives/edgar/data/1668243/000143774925006757/ex_785682.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-006757): "The FDA accepted the NDA for UGN-102 and assigned a PDUFA goal date of June 13, 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006757/ex_785682.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-005649): "With unprecedented data in LG-IR-NMIBC, we are focused on pre-commercial and launch activities for UGN-102 with a target PDUFA date of June 13, 2025 We continue to increase adoption of JELMYTO with recent Durability Data supporting continued use We have a strong balance sheet with focus on UGN-102 commercial execution, and strategic and efficient capital deployment Our next generation novel mitomycin formulations will provide an opportunity to extend our leadership in addressing unmet needs in Urothelial cancers Through Organic and In-Organic opportunities, we plan to build a long-term sustainable growth business 39" https://www.sec.gov/Archives/edgar/data/1668243/000119312525005649/d903812dex991.htm
- SEC Form 10-Q (accession 0001437749-25-015956): "While the FDA accepted our NDA for UGN-102 in October 2024 and assigned a PDUFA goal date of June 13, 2025, there is no guarantee that the PDUFA goal date will not be delayed or that the FDA will eventually approve UGN-102 for the indication and patient population that we request or approve the labeling that we believe is necessary or desirable for the successful commercialization of UGN-102, as the FDA does not always meet its PDUFA dates and it has the authority to refuse to approve NDAs for a variety of reasons." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-006842): "In October 2024, the FDA accepted our NDA for UGN-102 and assigned a PDUFA goal date of June 13, 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm
- SEC Form 10-Q (accession 0001437749-25-015956): "In October 2024, the FDA accepted the Company's NDA for UGN-102 (mitomycin) for intravesical solution and assigned a Prescription Drug User Fee Act ("PDUFA") goal date of June 13, 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm
- SEC Form 10-Q (accession 0001437749-25-015956): "In October 2024, the FDA accepted our NDA for UGN-102 (mitomycin) for intravesical solution and assigned a Prescription Drug User Fee Act ("PDUFA") goal date of June 13, 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925015956/urgn20250331_10q.htm
- SEC Form 10-K (accession 0001437749-25-006842): "In October 2024, the FDA accepted our NDA for UGN-102 (mitomycin) for intravesical solution and assigned a Prescription Drug User Fee Act ("PDUFA") goal date of June 13, 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm
- SEC Form 10-K (accession 0001437749-25-006842): "In October 2024, the FDA accepted the Company's NDA for UGN-102 (mitomycin) for intravesical solution and assigned a Prescription Drug User Fee Act ("PDUFA") goal date of June 13, 2025." https://www.sec.gov/Archives/edgar/data/1668243/000143774925006842/urgn20241231_10k.htm
- openFDA Drugs@FDA: "NDA215793 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250612, review_priority STANDARD; sponsor_name UROGEN PHARMA; product ZUSDURI (MITOMYCIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215793%22

### August 7, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-08-07, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-025242): "UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results" https://www.sec.gov/Archives/edgar/data/1668243/000143774925025242/ex_847591.htm

### November 6, 2025: earnings report

- Status: completed. Date confidence: exact.
- First seen 2025-11-06, last confirmed 2025-11-06.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-033466): "UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum" https://www.sec.gov/Archives/edgar/data/1668243/000143774925033466/ex_880398.htm

### May 6, 2026: earnings report

- Status: completed. Date confidence: exact.
- First seen 2026-05-06, last confirmed 2026-05-06.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-015018): "UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights" https://www.sec.gov/Archives/edgar/data/1668243/000143774926015018/ex_956006.htm

### Q3 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2025-11-06, last confirmed 2026-08-05.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-025793): "UroGen remains on track to submit a New Drug Application (NDA) for UGN-103 in the third quarter of 2026, with potential FDA approval in 2027 and full launch anticipated following receipt of a unique J-Code." https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/ex_995856.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-015018): "Continued advancement of next-generation pipeline, UGN-103 on track for NDA submission in the second half of 2026; six-month durability data expected in mid-2026" https://www.sec.gov/Archives/edgar/data/1668243/000143774926015018/ex_956006.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-033466): "UroGen anticipates submitting an NDA for UGN-103 in the second half of 2026 with potential approval anticipated in 2027." https://www.sec.gov/Archives/edgar/data/1668243/000143774925033466/ex_880398.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-006233): "UroGen plans to submit the NDA in the second half of 2026 with potential FDA approval in 2027." https://www.sec.gov/Archives/edgar/data/1668243/000143774926006233/ex_925621.htm

### Aug 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month. Stage: 3. Indication: with recurrent low-grade intermediate risk NMIBC supported.
- First seen 2026-11-04, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0001437749-26-034780): "In August 2026, we submitted an NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC supported by the clinical data from the ongoing Phase 3 UTOPIA trial, and in October 2026, we announced the FDA's acceptance of the NDA and the assignment of a Prescription Drug User Fee Act ("PDUFA") target action date of June 14, 2027." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm

### Oct 2026: NDA/BLA acceptance

- Status: completed. Date confidence: month.
- First seen 2026-11-04, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-034769): "In October 2026, the FDA accepted for review UroGen's NDA for UGN-103 and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 14, 2027." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: recurrent, papillary-only high-risk NMIBC.
- First seen 2026-08-05, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-034769): "UroGen plans to initiate the Phase 3 LONGVIEW-HR randomized, multicenter trial in the fourth quarter of 2026 evaluating adjuvant UGN-103 versus intravesical gemcitabine in patients with recurrent, papillary-only high-risk NMIBC who previously received Bacillus Calmette-Guérin (BCG) therapy." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-025793): "The Company expects to initiate a randomized controlled Phase 3 trial evaluating UGN-103 in high-risk NMIBC in the second half of 2026, and a trial evaluating UGN-103 as adjuvant therapy in newly diagnosed intermediate-risk NMIBC patients in 2027." https://www.sec.gov/Archives/edgar/data/1668243/000143774926025793/ex_995856.htm
- SEC Form 10-Q (accession 0001437749-26-034780): "As part of our life cycle management strategy for UGN-103, we are planning to initiate the Phase 3 LONGVIEW-HR trial in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-034769): "The Company also plans to initiate a non-registrational trial in 2027 evaluating the use of UGN-103 as adjuvant therapy in the newly diagnosed intermediate-risk NMIBC population." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm
- SEC Form 10-Q (accession 0001437749-26-034780): "We also plan to initiate a non-registrational trial in 2027 evaluating the use of UGN-103 as adjuvant therapy in the newly diagnosed intermediate-risk NMIBC population." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm

### June 14, 2027: PDUFA date

- Status: scheduled. Date confidence: exact. Stage: 3. Indication: with recurrent low-grade intermediate risk NMIBC.
- First seen 2026-11-04, last confirmed 2026-11-04.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-034769): "The FDA accepted UroGen's NDA for UGN-103 (next-generation novel mitomycin-based formulation) for review; PDUFA goal date set for June 14, 2027" https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-034769): "In October 2026, the FDA accepted for review UroGen's NDA for UGN-103 and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 14, 2027." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm
- SEC Form 10-Q (accession 0001437749-26-034780): "In August 2026, we submitted an NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC supported by the clinical data from the ongoing Phase 3 UTOPIA trial, and in October 2026, we announced the FDA's acceptance of the NDA and the assignment of a Prescription Drug User Fee Act ("PDUFA") target action date of June 14, 2027." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm
- SEC Form 10-Q (accession 0001437749-26-034780): "Our NDA for UGN-103 for the treatment of adults with recurrent low-grade intermediate risk NMIBC is presently under review by FDA with a PDUFA target action date of June 14, 2027." https://www.sec.gov/Archives/edgar/data/1668243/000143774926034780/urgn20260930_10q.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-034769): "the PDUFA target action date of June 14, 2027 may be delayed due to various factors outside UroGen's control" https://www.sec.gov/Archives/edgar/data/1668243/000143774926034769/ex_1036873.htm

Calendar months: [June 2027](https://sec-api.dev/fda-calendar/2027-06)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mitomycin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ZUSDURI (mitomycin) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mitomycin

```bibtex
@misc{secapidev_pdufa_mitomycin_20261116,
  title        = {ZUSDURI (mitomycin) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mitomycin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mitomycin_20261116","title":"ZUSDURI (mitomycin) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mitomycin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
